Intrahepatic Cholestasis of Pregnancy: A Maternal 911 Priority

Intrahepatic cholestasis in pregnancy (ICP) is a liver disorder unique to pregnant individuals, caused by reduced bile flow that leads to elevated bile acids in the blood. It usually develops during the third trimester and poses risks for both mother and baby. Early identification and proper management can significantly reduce complications.

Recognizing the Signs and Symptoms

The most common symptoms of ICP include:

• Severe itching (pruritus): Typically on the palms and soles, without a rash.
• Jaundice: Yellowing of the skin or eyes in some patients.
• Abnormal bile acid levels: A bile acid concentration of ≥10 µmol/L confirms diagnosis.

For a deeper overview of pruritus and other pregnancy-related conditions, visit the American Pregnancy Association’s page on ICP.

Maternal and Fetal Risks of ICP

Both maternal and fetal complications can arise from intrahepatic cholestasis in pregnancy:

Maternal Risks:

• Increased risk of long-term hepatobiliary diseases (RR 2.81)
• Elevated likelihood of hepatitis C infection (RR 4.02)

Fetal Risks:

• Higher chance of preterm birth (RR 2.11)
• Meconium-stained amniotic fluid (RR 1.91)
• Greater risk of stillbirth in severe cases

For patient-friendly guidance on maternal risk reduction, see Maternal 911’s Education Hub.

Diagnostic Approach for Cholestasis in Pregnancy

Accurate diagnosis is critical for managing intrahepatic cholestasis:

• Total Serum Bile Acids (TSBA): ≥10 µmol/L confirms diagnosis.
• Liver Function Tests: May show mild abnormalities.
• Exclude Other Conditions: Rule out viral hepatitis, gallstones, and autoimmune liver diseases.

Learn more about diagnostic standards from the Society for Maternal-Fetal Medicine.

Management and Treatment Strategies

Effective management of cholestasis in pregnancy focuses on maternal comfort and fetal safety:

• Ursodeoxycholic Acid (UDCA): Reduces bile acid levels and relieves itching.
• Fetal Surveillance: Regular non-stress tests and ultrasounds to track well-being.
• Planned Delivery: Induction often considered around 37–38 weeks, depending on case severity.
• Postpartum Recovery: Symptoms typically resolve within days to weeks after delivery.

For ongoing care strategies, explore Maternal 911’s Professional Training Programs.

Improving Maternal Outcomes

Intrahepatic cholestasis in pregnancy demands swift recognition and evidence-based management. Healthcare providers should remain vigilant in pregnant patients presenting with unexplained itching during the third trimester. Prompt intervention can dramatically improve maternal and fetal outcomes.

Click here to contact us with any questions.

References:

1. Hague WM et al. (2023). Intrahepatic cholestasis of pregnancy – Diagnosis and management. Aust N Z J Obstet Gynaecol.
2. Geenes V et al. (2014). Intrahepatic cholestasis of pregnancy: Maternal and fetal outcomes. Hepatology.
3. Zhao Y et al. (2023). Intrahepatic cholestasis of pregnancy and risk of hepatobiliary disease. Hepatology International.

Maternal 911 Education Systems, LLC is a leader in emergency obstetrics and team training, improving outcomes through education and evidence-based practice.

Maternal 911 Education Systems, LLC is led by a team of experts in emergency obstetrics and maternal safety, dedicated to improving outcomes through evidence-based, team-centered education. Passionate about maternal health education, Maternal 911 advocates for evidence-based practices and interdisciplinary team training. Their mission is to reduce pregnancy risks through education and emergency training. Learn more at maternal911.com.

Click here to contact us with any questions.

Educational use only — not a substitute for clinical judgment or local protocols.